Leerink Partners analyst Jason Gerberry cut his price target on Impax Laboratories (NASDAQ: IPXL) to $24.00 (from $33.00) following a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE